Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Su Jin Heo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08
Ki Hyang Kim, Joo Hoon Kim, Ji Young Lee, Hyo Song Kim, Su Jin Heo, Ji Hyung Kim, Ho Young Kim, Sun Young Rha
Cancer Res Treat. 2016;48(4):1286-1292.   Published online February 12, 2016
DOI: https://doi.org/10.4143/crt.2016.018
AbstractAbstract PDFPubReaderePub
Purpose
We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment.
Results
Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

Citations

Citations to this article as recorded by  
  • Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis
    Manuel Eros Rodríguez-Fuentes, Mario Pérez-Sayáns, Carmen Martín Carreras-Presas, Xabier Marichalar-Mendia, Leticia Bagán-Debón, Rafael López-López
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(3): 385.     CrossRef
  • Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
    Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka
    Cancer Chemotherapy and Pharmacology.2021; 87(6): 723.     CrossRef
  • Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
    Cristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, Giuseppe Procopio, Ugo de Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Francesco Atzori, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Guida, Annalisa B
    Clinical Genitourinary Cancer.2019; 17(1): e150.     CrossRef
  • Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials
    Ravi K. Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju
    Oncology Reviews.2019;[Epub]     CrossRef
  • 10,337 View
  • 144 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Case Report
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Res Treat. 2016;48(1):409-414.   Published online February 17, 2015
DOI: https://doi.org/10.4143/crt.2014.299
AbstractAbstract PDFPubReaderePub
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrenal gland, and pancreas. We herein describe the case of a 74-year-old man carrying the VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS.

Citations

Citations to this article as recorded by  
  • Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review
    Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611.     CrossRef
  • Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity
    Fnu Raja, Vinesh Kumar, Azzam Hammad, Caroline Abramovich
    Cureus.2023;[Epub]     CrossRef
  • VHL syndrome without clear family history: A rare case report and literature review of Chinese patients
    Yaheng Li, Xiaohong Xin, Wenzhu Song, Xuan Zhang, Shengli Chen, Qian Wang, Aizhong Li, Yafeng Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Von Hipple-Lindau disease complicated with central retinal vein occlusion: a case report
    Xingwang Chen, Mengyao Wang, Yuan Tang, Bing Xie, Xiaomei Nie, Shanjun Cai
    BMC Ophthalmology.2022;[Epub]     CrossRef
  • Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome
    Yuhao Zhou, Jian Liu, Liangzhao Chu, Minghao Dong, Luqian Feng
    World Neurosurgery.2021; 150: e696.     CrossRef
  • Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor
    Lukas Oberhammer, Michael Josef Mitterberger, Lukas Lusuardi, Thomas Kunit, Martin Drerup, Daniela Colleselli, Hubert Griessner, Martina Hager
    Clinical Case Reports.2019; 7(12): 2321.     CrossRef
  • MicroRNA Assisted Gene Regulation in Colorectal Cancer
    Adewale Fadaka, Ashley Pretorius, Ashwil Klein
    International Journal of Molecular Sciences.2019; 20(19): 4899.     CrossRef
  • 12,861 View
  • 101 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Original Article
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
Choong-kun Lee, Minkyu Jung, Hye Jin Choi, Hye Ryun Kim, Hyo Song Kim, Mi Ryung Roh, Joong Bae Ahn, Hyun Cheol Chung, Su Jin Heo, Sun Young Rha, Sang Joon Shin
Cancer Res Treat. 2015;47(4):781-789.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.261
AbstractAbstract PDFPubReaderePub
Purpose
There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. Materials and Methods We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR).
Results
Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). Conclusion Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine.

Citations

Citations to this article as recorded by  
  • Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals
    Courtney R. Croley, Joshua Pumarol, Blake E. Delgadillo, Andrew C. Cook, Faith Day, Tea Kaceli, Caroline C. Ward, Imran Husain, Ali Husain, Sabyasachi Banerjee, Anupam Bishayee
    Pharmacology & Therapeutics.2023; 248: 108479.     CrossRef
  • A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
    Pui Ying Chan, Melissa M. Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M. L. Cohen, Mandeep S. Sagoo, John S. Bomalaski, Michael T. Sheaff, Peter W. Szlosarek
    Pigment Cell & Melanoma Research.2022; 35(4): 461.     CrossRef
  • iUMRG: multi-layered network-guided propagation modeling for the inference of susceptibility genes and potential drugs against uveal melanoma
    Yueping Ren, Congcong Yan, Lili Wu, Jingting Zhao, Mingwei Chen, Meng Zhou, Xiaoyan Wang, Tonghua Liu, Quanyong Yi, Jie Sun
    npj Systems Biology and Applications.2022;[Epub]     CrossRef
  • Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives
    Francesca Comito, Paola Valeria Marchese, Angela Dalia Ricci, Nastassja Tober, Chiara Peterle, Francesca Sperandi, Barbara Melotti
    Future Oncology.2021; 17(33): 4583.     CrossRef
  • New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review
    Mario Damiano Toro, Lucia Gozzo, Luciano Tracia, Marco Cicciù, Filippo Drago, Claudio Bucolo, Teresio Avitabile, Robert Rejdak, Katarzyna Nowomiejska, Sandrine Zweifel, Yacoub A. Yousef, Rashed Nazzal, Giovanni Luca Romano
    Biomedicines.2021; 9(10): 1311.     CrossRef
  • Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma
    Shenglong Li, Xixi Wu, Peng Chen, Yi Pei, Ke Zheng, Wei Wang, Enduo Qiu, Xiaojing Zhang
    Anti-Cancer Drugs.2019; 30(4): 402.     CrossRef
  • Mechanism of HN‑3 cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca2+ and the nucleus pathways
    Bo Shen, Wenjing Mao, Jin‑Chul Ahn, Phil‑Sang Chung, Peijie He
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment
    Mohamed Hassan
    World Journal of Experimental Medicine.2015; 5(4): 206.     CrossRef
  • 13,562 View
  • 105 Download
  • 7 Web of Science
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP